BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 21170507)

  • 1. Thiazolidinediones/PPARγ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer.
    Mansour M; Schwartz D; Judd R; Akingbemi B; Braden T; Morrison E; Dennis J; Bartol F; Hazi A; Napier I; Abdel-Mageed AB
    Int J Oncol; 2011 Feb; 38(2):537-46. PubMed ID: 21170507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma.
    Shiau CW; Yang CC; Kulp SK; Chen KF; Chen CS; Huang JW; Chen CS
    Cancer Res; 2005 Feb; 65(4):1561-9. PubMed ID: 15735046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KLF5 enhances SREBP-1 action in androgen-dependent induction of fatty acid synthase in prostate cancer cells.
    Lee MY; Moon JS; Park SW; Koh YK; Ahn YH; Kim KS
    Biochem J; 2009 Jan; 417(1):313-22. PubMed ID: 18774944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer.
    Lin MS; Chen WC; Bai X; Wang YD
    J Dig Dis; 2007 May; 8(2):82-8. PubMed ID: 17532820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Fatty Acid Synthase (FASN) synergistically enhances the efficacy of 5-fluorouracil in breast carcinoma cells.
    Vazquez-Martin A; Ropero S; Brunet J; Colomer R; Menendez JA
    Oncol Rep; 2007 Oct; 18(4):973-80. PubMed ID: 17786362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines.
    Yang FG; Zhang ZW; Xin DQ; Shi CJ; Wu JP; Guo YL; Guan YF
    Acta Pharmacol Sin; 2005 Jun; 26(6):753-61. PubMed ID: 15916743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peroxisome proliferator-activated receptor gamma-independent suppression of androgen receptor expression by troglitazone mechanism and pharmacologic exploitation.
    Yang CC; Wang YC; Wei S; Lin LF; Chen CS; Lee CC; Lin CC; Chen CS
    Cancer Res; 2007 Apr; 67(7):3229-38. PubMed ID: 17409431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rosiglitazone increases PPARgamma in renal tubular epithelial cells and protects against damage by hydrogen peroxide.
    Sommer M; Wolf G
    Am J Nephrol; 2007; 27(4):425-34. PubMed ID: 17622750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones.
    Weng JR; Chen CY; Pinzone JJ; Ringel MD; Chen CS
    Endocr Relat Cancer; 2006 Jun; 13(2):401-13. PubMed ID: 16728570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo.
    Kubota T; Koshizuka K; Williamson EA; Asou H; Said JW; Holden S; Miyoshi I; Koeffler HP
    Cancer Res; 1998 Aug; 58(15):3344-52. PubMed ID: 9699665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated protein kinase: implications for diabetes-impaired skin repair.
    Schiefelbein D; Seitz O; Goren I; Dissmann JP; Schmidt H; Bachmann M; Sader R; Geisslinger G; Pfeilschifter J; Frank S
    Mol Pharmacol; 2008 Oct; 74(4):952-63. PubMed ID: 18599600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New troglitazone derivatives devoid of PPARγ agonist activity display an increased antiproliferative effect in both hormone-dependent and hormone-independent breast cancer cell lines.
    Colin C; Salamone S; Grillier-Vuissoz I; Boisbrun M; Kuntz S; Lecomte J; Chapleur Y; Flament S
    Breast Cancer Res Treat; 2010 Nov; 124(1):101-10. PubMed ID: 20054646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor gamma in vascular smooth muscle cells.
    Bruemmer D; Yin F; Liu J; Berger JP; Sakai T; Blaschke F; Fleck E; Van Herle AJ; Forman BM; Law RE
    Circ Res; 2003 Aug; 93(4):e38-47. PubMed ID: 12881480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of rosiglitazone--peroxisome proliferators-activated receptor gamma (PPARgamma) agonist on cell viability of human pituitary adenomas in vitro.
    Winczyk K; Kunert-Radek J; Gruszka A; Radek M; Ławnicka H; Pawlikowski M
    Neuro Endocrinol Lett; 2009 Mar; 30(1):107-10. PubMed ID: 19300395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PPARγ-inactive Δ2-troglitazone independently triggers ER stress and apoptosis in breast cancer cells.
    Colin-Cassin C; Yao X; Cerella C; Chbicheb S; Kuntz S; Mazerbourg S; Boisbrun M; Chapleur Y; Diederich M; Flament S; Grillier-Vuissoz I
    Mol Carcinog; 2015 May; 54(5):393-404. PubMed ID: 24293218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo.
    Yu J; Qiao L; Zimmermann L; Ebert MP; Zhang H; Lin W; Röcken C; Malfertheiner P; Farrell GC
    Hepatology; 2006 Jan; 43(1):134-43. PubMed ID: 16374840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.
    Díaz-Delfín J; Morales M; Caelles C
    Diabetes; 2007 Jul; 56(7):1865-71. PubMed ID: 17416798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disruption of ERalpha signalling pathway by PPARgamma agonists: evidences of PPARgamma-independent events in two hormone-dependent breast cancer cell lines.
    Lecomte J; Flament S; Salamone S; Boisbrun M; Mazerbourg S; Chapleur Y; Grillier-Vuissoz I
    Breast Cancer Res Treat; 2008 Dec; 112(3):437-51. PubMed ID: 18204896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peroxisome proliferator-activated receptor gamma-independent effects of thiazolidinediones on human cardiac myofibroblast function.
    Mughal RS; Warburton P; O'Regan DJ; Ball SG; Turner NA; Porter KE
    Clin Exp Pharmacol Physiol; 2009 May; 36(5-6):478-86. PubMed ID: 19673929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary culture model of peroxisome proliferator-activated receptor gamma activity in prostate cancer cells.
    Xu Y; Iyengar S; Roberts RL; Shappell SB; Peehl DM
    J Cell Physiol; 2003 Jul; 196(1):131-43. PubMed ID: 12767049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.